ERBB2 and neoplasm: Overall the prognostic model based on the six subtypes defined by five IHC markers fits significantly better than a model based on three subtypes—ER-positive or PR-positive and HER2-negative, HER2-positive, and triple-negative tumours—defined by the three markers currently in standard clinical practice (likelihood ratio chisq = 54.4, 3 degrees of freedom [df], p<0.0001).